Condition: Advanced Unresectable Gastric Adenocarcinoma · Esophageal Squamous Cell Carcinoma · Advanced Gastroesophageal Adenocarcinoma · Sponsor: BeOne Medicines
The purpose of this study is to characterize the clinical effects of tislelizumab, including pharmacokinetics (PK), activity, and safety assessments in US racial and ethnic minority patients with human epidermal growth factor receptor 2 (HER2)-negative, programmed death-ligand 1(PD-L1)-positive, unresectable or metastatic gastric or gastroesophageal cancer (GAC/GEA) or esophageal squamous cell carcinoma (ESCC). The study duration will be up to approximately 6 years.
This description comes directly from the study's public registry record.
Study Director · 1-877-828-5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| Los Angeles Cancer Network | Los Angeles, California, United States | Recruiting |
| Bioresearch Partners Holding Hialeah Hospital | Hialeah, Florida, United States | Recruiting |
| Florida Clinical Trials Group Plantation | Plantation, Florida, United States | Recruiting |
| Florida Clinical Trials Group Tamarac | Tamarac, Florida, United States | Recruiting |
| Washington University School of Medicine | St Louis, Missouri, United States | Recruiting |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07554521